Hypothesis

Age‑associated mitochondrial dysfunction increases ROS production in dermal fibroblasts and chondrocytes, which activates DNMT3A‑mediated methylation of the HAS2 promoter. This epigenetic repression reduces HMW‑HA synthesis, shifts the HA fragment spectrum toward LMW‑HA (100–400 kDa), and amplifies TLR2/4‑NF‑κB signaling locally and systemically. Restoring mitochondrial NAD⁺ levels with nicotinamide riboside (NR) will reduce ROS, diminish DNMT3A activity, reactivate HAS2 expression, and lower circulating LMW‑HA, thereby attenuating both skin inflammation and joint osteoarthritis.

Rationale

• et al. show that HAS2 downregulation in aging dermis and joints correlates with LMW‑HA‑driven TLR2/4 activation and NF‑κB cytokine release {1; 2}.
• Mitochondrial ROS are known to upregulate DNMT3A and promote promoter methylation in senescence models {3}.
• NAD⁺ boosters such as NR improve mitochondrial function and reduce ROS in aged tissues {4}.
• No study has directly linked mitochondrial ROS → DNMT3A → HAS2 silencing → LMW‑HA accumulation in the skin‑joint axis.

Predictions

1. In aged mouse skin and cartilage, mitochondrial ROS levels will positively correlate with DNMT3A occupancy at the HAS2 promoter and inversely with HAS2 mRNA.
2. NR supplementation will decrease mitochondrial ROS, reduce DNMT3A binding, increase HAS2 transcription, and shift HA distribution toward HMW‑HA (>1 MDa).
3. Consequently, serum LMW‑HA concentrations will drop, TLR2/4 signaling in fibroblasts and chondrocytes will be attenuated, and downstream cytokines (TNFα, IL‑1β, IL‑6) will decline.
4. Functional outcomes: improved skin barrier metrics (reduced TEWL, lower IL‑36 release) and decreased OARSI/Mankin scores in joint cartilage.
5. Genetic or pharmacologic inhibition of DNMT3A will phenocopy NR’s effects, confirming the epigenetic mediator.

Experimental Design

• Animals: 24‑month‑old C57BL/6 mice (n=10/group) vs. 3‑month‑old controls. Groups: vehicle, NR (400 mg/kg/day orally), DNMT3A siRNA via topical nanoparticle delivery (skin) and intra‑articular injection (joint).
• Measurements (after 8 weeks):
  • Mitochondrial ROS (MitoSOX fluorescence) in isolated fibroblasts/chondrocytes.
  • DNMT3A ChIP‑qPCR at HAS2 promoter CpG islands.
  • HAS2 mRNA (RT‑qPCR) and protein (Western).
  • HA size distribution by SEC‑MALS from tissue extracts and serum.
  • TLR2/4‑NF‑κB activity (luciferase reporter in primary cells).
  • Cytokine panel (ELISA).
  • Skin IL‑36 ELISA, TEWL, histology.
  • Joint OARSI scoring, Safranin‑O staining, Mankin index.
• Controls: Young mice ± NR to rule out developmental effects; ROS scavenger (NAC) arm to dissect ROS‑specificity.

Potential Outcomes and Falsifiability

• Support: NR (or DNMT3A knockdown) restores HAS2, reduces LMW‑HA, dampens TLR/NF‑κB signaling, and improves skin/joint phenotypes.
• Refutation: If NR fails to alter DNMT3A binding, HAS2 expression, or HA fragment size despite lowering ROS, the mitochondrial ROS → DNMT3A → HAS2 axis is not operative. Likewise, if LMW‑HA levels remain high or joint/skin pathology persists, the hypothesis is falsified.
• This design directly tests the mechanistic link between mitochondrial epigenetics and the HA‑mediated skin‑joint inflammatory axis proposed by et al. {5; 6}}